1. WHI Cancer Survivor Cohort (CSC)
Multiple PIs: Garnet Anderson, Bette Caan, and Electra Paskett
Funded by the NCI 1

2. Life and Longevity After Cancer (LILAC)
Specific Activities:
Obtain information on cancer treatment and outcomes from multiple sources for women with selected cancers
Self-report (Baseline and annual questionnaires)
Medicare
Medical record review
Collect tumor tissue (FFPE blocks/slides)
Conduct survivorship research among women who complete baseline and annual surveys

3. Potential Cancers Under Study
Cancer Site
Incident Cases
( )
Prevalent Cases (2010)
Total Cases (2015)
Breast
2373
9756
12,129
Colorectal
624
2337
2961
Endometrial
328
1331
1659
Ovarian
256
875
1131
Lung
1371
2115
3486
Melanoma
792
1314
2106
Lymphoma
590
975
1565
Leukemia
399
523
922
Total
6,733
19,226
25,959 3

4. LILAC Survey Response Baseline (Form 340) Annual (Form 370)
Cancer Site
Mailed
Completed %
Breast
5,352
4,291
80.2
Colorectal
1,053
802
76.2
Endometrial
847
661
78.0
Fallopian 28 24
85.7
Leukemia
260
186
71.5
Lung
568
415
73.1
Lymphoma
595
452
76.0
Melanoma
1,206
864
71.6
Ovarian
206
171
83.0
Peritoneum 25 20
80.0
Total
10,140
7,886
77.8
Cancer Site
Mailed
Completed %
Breast
3,870
3,570
92.2
Colorectal
726
643
88.6
Mlt Primary 10 9
90.0
Endometrial
602
537
89.2
Fallopian 21 18
85.7
Leukemia
154
126
81.8
Lung
339
291
85.8
Lymphoma
409
361
88.3
Melanoma
451
403
89.4
Ovarian
137
123
89.8
Peritoneum 17 15
88.2
Total
6,736
6,096
90.5

5. LILAC Tissue Collection
Cancer Site
Tissue Eligible1
Requested
Received
Destroyed
Slides Only2
Breast
3,471
2,295
1,237
249
1,041
Colorectal
946
874
537 96
284
Endometrial
619
335
173 49
186
Lung
836
228
103 31
251
Melanoma (in situ)
334
258
137 22
100
Melanoma (invasive)
444
362
195 38
133
Ovarian
409
273
122 37
123
Total
7,059
4,625
2,504
522
2,118
1. Cases for ppts living and consented or deceased. Diagnosed 2002 or later, tumor size > 3 mm, excluding sarcomas. New cases to be enrolled Jan
2. Estimated. Requests starting in Dec. 2015, beginning with colorectal cases.

6. Update on Treatment Information
Cancer Site
Treatment Data Eligible*
Tx Data Now Available
Source: Medical records
Source:
Medicare
Breast
5,916
5,240
1,954
3,286
Colorectal
1,746
1,682
716
966
Endometrial
1,019
559 3
556
Ovarian
784
574
240
334
Lung
2,305
1,337
239
1,098
Melanoma
645
333 21
312
Lymphoma
972
530
Leukemia
615
363
Total
14,002
10,618
3,173
7,445
Medical Records
1st pass
final
Total
Available for
Done
in CMS
analysis
Breast cancer
2630
2863
1528
3286
4814
Colorectal cancer
772
521
966
1487
Endometrial Cancer
459
556
Lung Cancer
1169
1098
Ovarian Cancer
446
119 46
334
380
Leukemia
244
312
Melanoma
330 28 3
363
366
NHL
438
530
* Cases consented to LILAC or deceased, who were diagnosed ≥2000 or in CMS FFS

7. Selected Characteristics of Survivorship Cohort
Variable*
Breast
(n=3349)
Ovary
(n=120)
Endomet
(n=502)
Colon
(n=580)
Lung
(n=245)
Melano
(n=352)
NHL
(n=321)
Leukemia
(n=114)
Yrs from Dx
(mean)
8.3
6.8
8.2
7.9
5.6
7.7
6.6
Chemo**
30%
91%
10%
34%
23% 3%
70%
40%
Recur-rence** 9%
31% 5% 8%
20%
17%
18% 6%
*Women who completed both F340 and F370
**Self-reported data

8. Renewal plans March 2017 submission Infrastructure to include
Tissue collection, and where necessary medical records collection of prospective cases
Follow-up of cohort for cancer outcomes
Analytic and general resource support
Methodology
Statistical methods
Continued efforts on validation of CMS cancer outcomes

9. Potential motivating science
Diet/PA/body composition & survival
Stress/sleep/inflammation/immune system
Host and tumor genomics
Cancer among the elderly
Comorbidities, non-cancer outcomes
Patterns of care
Other?

10. Timeline Solicit concept (2 pages) by November 1
Organize working groups around themes (Nov/Dec)
Determine infrastructure needs (budget) for these R01s (Dec 1)
Submit LOI by January 10
EAB review in late January
March 10, 2017 submission